Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Literature DB >> 17541600

The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Bernard Paule¹, Stéphane Terry, Laurence Kheuang, Pascale Soyeux, Francis Vacherot, Alexandre de la Taille.

Abstract

The nuclear factor of kappa beta (NF-kappaB) transcription factor regulates the transcription of numerous genes including that of interleukin 6 (IL-6). The IL-6 acts as an autocrine and paracrine growth factor of androgen-independent prostate cancer. An aberrant expression of the IL-6 gene and an increase in IL-6 expression are detected in bone metastatic and hormone-refractory prostate cancer. IL-6 has been suggested to have a crucial role in the resistance to chemotherapy or hormonal therapy involving apoptotic cell death. The NF-kappaB/IL-6 dependent pathways promote tumour-cell survival and in most situations protect cells against apoptotic stimuli. These data provide a rational framework for targeting NF-kappaB and IL-6 activity in novel biologically based therapies for aggressive and androgen independent prostate cancers.

Entities: Disease Gene

Mesh：

Substances：
Interleukin-6
NF-kappa B

Year: 2007 PMID： 17541600 DOI： 10.1007/s00345-007-0175-6

Source DB: PubMed Journal: World J Urol ISSN： 0724-4983 Impact factor: 4.226

112 in total

1. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.

Authors: Sichuan Xi; William E Gooding; Jennifer Rubin Grandis
Journal: Oncogene Date: 2005-02-03 Impact factor: 9.867

2. Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors: D Giri; M Ozen; M Ittmann
Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307

3. Stat3 activation in prostatic carcinomas.

Authors: Rajiv Dhir; Zuyao Ni; Wei Lou; Fernando DeMiguel; Jennifer Rubin Grandis; Allen C Gao
Journal: Prostate Date: 2002-06-01 Impact factor: 4.104

4. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells.

Authors: Cécile Le Page; Ismael Hervé Koumakpayi; Laurent Lessard; Anne-Marie Mes-Masson; Fred Saad
Journal: Prostate Date: 2005-10-01 Impact factor: 4.104

Review 5. Akt in prostate cancer: possible role in androgen-independence.

Authors: Paramita M Ghosh; Shazli Malik; Roble Bedolla; Jeffrey I Kreisberg
Journal: Curr Drug Metab Date: 2003-12 Impact factor: 3.731

6. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.

Authors: Jae-Il Park; Min-Goo Lee; Kyucheol Cho; Bum-Joon Park; Kwon-Seok Chae; Do-Sun Byun; Byung-Kyu Ryu; Yong-Keun Park; Sung-Gil Chi
Journal: Oncogene Date: 2003-07-10 Impact factor: 9.867

7. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors: Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701

8. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Authors: A Hobisch; I E Eder; T Putz; W Horninger; G Bartsch; H Klocker; Z Culig
Journal: Cancer Res Date: 1998-10-15 Impact factor: 12.701

9. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors: W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal: Clin Cancer Res Date: 1999-01 Impact factor: 12.531

10. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.

Authors: Alexander V Gasparian; Ya Juan Yao; Dariusz Kowalczyk; Ludmila A Lyakh; Apollon Karseladze; Thomas J Slaga; Irina V Budunova
Journal: J Cell Sci Date: 2002-01-01 Impact factor: 5.285

32 in total

1. Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli.

Authors: Anahita Hamidi; Verena von Bulow; Rosita Hamidi; Nicolas Winssinger; Sofia Barluenga; Carl-Henrik Heldin; Marene Landström
Journal: J Biol Chem Date: 2011-11-08 Impact factor: 5.157

2. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors: Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal: World J Urol Date: 2008-04-05 Impact factor: 4.226

3. Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.

Authors: J C Evans; J McCarthy; C Torres-Fuentes; J F Cryan; J Ogier; R Darcy; R W Watson; C M O'Driscoll
Journal: Gene Ther Date: 2015-05-25 Impact factor: 5.250

4. Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells.

Authors: Xingchuan Wei; Zhi-Yun DU; Xiao-Xing Cui; Michael Verano; Rong Qing Mo; Zhi Kai Tang; Allan H Conney; Xi Zheng; Kun Zhang
Journal: Oncol Lett Date: 2012-05-10 Impact factor: 2.967

Review 5. Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors: J L Sottnik; E T Keller
Journal: Curr Mol Med Date: 2013-05 Impact factor: 2.222

6. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma.

Authors: Shan Ke; Xue-mei Ding; Jian Kong; Jun Gao; Shao-hong Wang; Yan Cheng; Wen-bing Sun
Journal: J Transl Med Date: 2010-07-29 Impact factor: 5.531